Bayülkem K, Erişir K, Tuncel A, Bayülkem B
Department of Neurology, Haseki Hospital, Ministry of Health, Istanbul, Turkey.
Adv Neurol. 1996;69:519-30.
Seventeen idiopathic parkinsonian patients ranging between 47 and 75 years of age were included in this study to investigate the effect and tolerance of lisuride on PD. The duration of this simple clinical study, which had no control group was 12 weeks. There was 50% relief in disability scores and ADL in 13 patients in the first group in the combined therapy for 12 weeks with lisuride added to L-DOPA plus benserazide (p < 0.01). Optimal lisuride doses added to L-DOPA plus benserazide varied between 0.1 and 0.8 mg (mean 0.5 +/- 0.2 mg). With the addition of lisuride to treatment, the L-DOPA plus benserazide dose was reduced in 6 of 13 by 38%. Monotherapy with lisuride resulted in 56% to 57% improvement in disability scores and 47% in relief in ADL. Dry mouth, nausea, weakness, postural hypotension, and headache were the most frequently encountered side effects of lisuride. These adverse effects disappeared in 3 or 4 days, depending on a slight decrease and following increase in the dose of lisuride and/or the development of tolerance. Not only will such a combined therapy contribute to the reduction of the end-of-dose inadequacies, on-off phenomena, wearing off, peak-dose dyskinesias, and similar motor fluctuations, it may also play a prophylactic role in their prevention or delay.
本研究纳入了17名年龄在47至75岁之间的特发性帕金森病患者，以调查利苏力特对帕金森病的疗效和耐受性。这项无对照组的简单临床研究为期12周。在第一组中，13名患者在左旋多巴加苄丝肼联合治疗12周并添加利苏力特后，残疾评分和日常生活活动能力有50%的改善（p<0.01）。添加到左旋多巴加苄丝肼中的最佳利苏力特剂量在0.1至0.8毫克之间（平均0.5±0.2毫克）。添加利苏力特进行治疗后，13名患者中有6名的左旋多巴加苄丝肼剂量减少了38%。利苏力特单药治疗使残疾评分改善了56%至57%，日常生活活动能力改善了47%。口干、恶心、虚弱、体位性低血压和头痛是利苏力特最常出现的副作用。这些不良反应在3至4天内消失，这取决于利苏力特剂量的轻微减少和随后的增加以及耐受性的发展。这样的联合治疗不仅有助于减少剂末疗效减退、开关现象、疗效减退、剂峰异动症及类似的运动波动，还可能在预防或延缓这些情况方面发挥预防作用。
